- Raw materials
- Antibacterials
- Pristinamycin
Pristinamycin API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Pristinamycin | CAS No: 270076-60-3 | GMP-certified suppliers
A medication that provides systemic antibacterial treatment for resistant Gram-positive bacterial infections, requiring careful quality control and monitoring in pharmaceutical development.
Therapeutic categories
Product Snapshot
- Pristinamycin is an oral antibiotic small molecule formulation
- It is primarily used for bacterial infections, particularly those caused by Gram-positive pathogens
- The compound is currently in experimental and investigational stages without approved regulatory status in major markets
Clinical Overview
Although pristinamycin is currently designated as experimental and investigational, it has been utilized primarily in the treatment of infections caused by Gram-positive bacteria, including strains resistant to other antibiotic classes. Its mechanism involves binding to the 50S subunit of the bacterial ribosome, interfering with peptide elongation. This dual component of streptogramin antibiotics often results in a synergistic antimicrobial effect.
Key pharmacokinetic properties of pristinamycin, such as absorption, distribution, metabolism, and elimination, are characterized by adequate bioavailability for systemic treatment, metabolism primarily through hepatic pathways, and excretion via biliary and renal routes. Understanding these parameters is critical to optimizing dosing regimens in clinical settings.
Safety and toxicity profiles must be monitored carefully due to the potential for allergic reactions, hepatic enzyme elevations, and gastrointestinal disturbances. Resistance development is a concern with streptogramins and should be considered in stewardship practices.
Pristinamycin’s CAS registry number is 270076-60-3, serving as a unique identifier for sourcing and regulatory documentation. The compound is used mainly in specialized clinical contexts where resistance patterns necessitate alternative therapies.
From a sourcing perspective, quality control is essential to ensure the API meets stringent purity standards and complies with relevant pharmacopeial specifications. Due diligence in supplier qualification and analytical verification supports consistent product quality for pharmaceutical development and manufacturing.
Identification & chemistry
| Generic name | Pristinamycin |
|---|---|
| Molecule type | Small molecule |
| CAS | 270076-60-3 |
| UNII | 4O8O7Q7IU4 |
| DrugBank ID | DB13704 |
Formulation & handling
- Pristinamycin is a small molecule antibiotic primarily intended for oral administration.
- The compound's stability profile requires protection from moisture and light during storage.
- Due to limited pharmacokinetic data, formulation strategies should consider potential food-drug interactions.
Regulatory status
Pristinamycin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
